TEV-‘333 / Teva, mAbxience - LARVOL DELTA

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate (GlobeNewswire) - "Teva Pharmaceuticals International GmbH...and mAbxience...today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate...The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience's strategy for global expansion...Similar to the initial contract, under the terms of this agreement, mAbxience will lead the development and production of the biosimilar, utilizing its state-of-the-art, cGMP-compliant facilities in Spain and Argentina. Teva will manage regulatory approvals and oversee commercialization in the designated markets, ensuring that patients around the world gain access to this oncology treatment."

Licensing / partnership • Oncology